A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

What is the difference between Ozempic, Wegovy and Mounjaro? Curbs will have to be put on which patients are to be eligible for weight loss jabs Mounjaro and Wegovy when they are added to HSE ...

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...

A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds.